RichardPaulJunghansMD

Oncology • Boston, MA

Associate Professor, Medicine, Boston University Sch of Med

Join to view full profile

Are you Dr. Junghans?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 62 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
800 Washington St
Boston, MA 02111
Phone+1 617-636-5982
Is this information wrong?

Summary

Dr. Richard Junghans, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts and Rhode Island. He is affiliated with Morton Hospital and Medical Center and is an Associate Professor at Boston University Sch of Med.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1983 - 1986
University of Miami Leonard M. Miller School of MedicineClass of 1983

Certifications & Licensure

MA State Medical License 1991 - 2026
RI State Medical License 2004 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Start of enrollment: 1995 Jul 01
Completed
Phase 1, Phase 2
Gene Therapy in Treating Patients With Cancer Start of enrollment: 1998 Apr 01
Completed
Phase 1
Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer Start of enrollment: 2007 Jul 01
Withdrawn
Phase 1
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning Start of enrollment: 2008 Apr 01
Suspended
Phase 1
Trial of Second Generation Designer T Cells in Colorectal Carcinoma Start of enrollment: 2008 May 01
Terminated
Phase 1
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer Start of enrollment: 2008 May 01
Suspended
Phase 1
Join now to see all

Publications & Presentations

PubMed

6 citations
Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice
Ancy Thomas, Saurav Sumughan, Emilia R. Dellacecca, Rohan Shivde, Nicola Lancki, Zhussipbek Mukhatayev, Cristina C. Vaca, Fei Han, Levi Barse, Steven W. Henning, Jesus...> ;JCI Insight. 2021 Nov 22
32 citations
Antigen Specificity Enhances Disease Control by Tregs in Vitiligo
Zhussipbek Mukhatayev, Emilia R. Dellacecca, Cormac Cosgrove, Rohan Shivde, Dinesh Jaishankar, Katherine Pontarolo-Maag, Jonathan M. Eby, Steven W. Henning, Yekaterina...> ;Frontiers in Immunology. 2020 Dec 1
35 citations
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.
Steven C. Katz, Ashley E. Moody, Prajna Guha, John C. Hardaway, Ethan A. Prince, Jason Laporte, Mirela Stancu, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick...> ;Journal for Immunotherapy of Cancer. 2020 Aug 1
Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
Jang Hwan Cho, Atsushi Okuma, Dalal Al-Rubaye, Ejaj Intisar, Richard P. Junghans, Wilson W. Wong> ;Scientific Reports. 2020 Feb 14
53 citations
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases.
Steven C. Katz, John C. Hardaway, Ethan A. Prince, Prajna Guha, Marissa Cunetta, Ashley E. Moody, Li Juan Wang, Vincent Armenio, N. Joseph Espat, Richard P. Junghans> ;Cancer Gene Therapy. 2020 May 1
82 citations
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
Prajna Guha, Jillian Gardell, Josephine Darpolor, Marissa Cunetta, Matthew Lima, George Miller, N. Joseph Espat, Richard P. Junghans, Steven C. Katz> ;Oncogene. 2019 Jan 1
38 citations
YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells
Mumtaz Yaseen Balkhi, Gábor Wittmann, Fang Xiong, Richard P. Junghans> ;Iscience. 2018 Apr 27
19 citations
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Kenneth Cornetta, Lisa Duffy, Steven A. Feldman, Crystal L. Mackall, Marco L. Davila, Kevin J. Curran, Richard P. Junghans, Jean Yuh Tang, James N. Kochenderfer, Roisi...> ;Molecular Therapy. Methods & Clinical Development. 2018 Sep 21
35 citations
Engineering Axl specific CAR and SynNotch receptor for cancer therapy.
Jang Hwan Cho, Atsushi Okuma, Dalal Al-Rubaye, Ejaj Intisar, Richard P. Junghans, Wilson W. Wong> ;Scientific Reports. 2018 Mar 1
18 citations
Oral Tranexamic Acid Reduces Transfusions in Total Knee Arthroplasty.
R. Perreault, Christine A. Fournier, David A. Mattingly, Richard P. Junghans, Carl T. Talmo> ;The Journal of Arthroplasty. 2017 Oct 1
34 citations
Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression
Prajna Guha, Marissa Cunetta, Ponnandai Somasundar, N. Joseph Espat, Richard P. Junghans, Steven C. Katz> ;Journal of Leukocyte Biology. 2017 Aug 1
22 citations
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.
Richard P. Junghans> ;Cancer Gene Therapy. 2017 Mar 1
183 citations
Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical re...
Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore, Erica M. Gomes, Anthony Bais, Agnes Lo, Mehrdad Abedi, Robin Davies, Howard Cabral, A. Samer Al-Homsi, Stephen I. C...> ;The Prostate. 2016 Oct 1
78 citations
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
Mitchell Thorn, Prajna Guha, Marissa Cunetta, N J Espat, George Miller, Richard P. Junghans, Steven C. Katz> ;Cancer Gene Therapy. 2016 May 20
114 citations
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
Steven C. Katz, Gary Point, Marissa Cunetta, Mitchell Thorn, Prajna Guha, N J Espat, Cherif Boutros, Nader Hanna, Richard P. Junghans> ;Cancer Gene Therapy. 2016 Apr 15
35 citations
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
John E. Janik, John C. Morris, Deirdre O'Mahony, Stefania Pittaluga, Elaine S. Jaffe, Christophe E. Redon, William M. Bonner, Martin W. Brechbiel, Chang H. Paik, Milli...> ;Proceedings of the National Academy of Sciences of the United States of America. 2015 Oct 20
158 citations
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Rachel A. Burga, Mitchell Thorn, Gary Point, Prajna Guha, Cang T. Nguyen, Lauren A. Licata, Ronald P. DeMatteo, Alfred Ayala, N. Joseph Espat, Richard P. Junghans, Ste...> ;Cancer Immunology, Immunotherapy. 2015 Apr 8
267 citations
Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases
Steven C. Katz, Rachel A. Burga, Elise McCormack, Li Juan Wang, Wesley Mooring, Gary Point, Pranay D. Khare, Mitchell Thorn, Qiangzhong Ma, Brian F. Stainken, Earle O....> ;Clinical Cancer Research. 2015 Apr 7
41 citations
T cell exhaustion and Interleukin 2 downregulation
Mumtaz Yaseen Balkhi, Qiangzhong Ma, Shazia Ahmad, Richard P. Junghans> ;Cytokine. 2015 Feb 1
29 citations
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.
Abdul Saied, Lauren A. Licata, Rachel A. Burga, Mitchell Thorn, Elise McCormack, Brian F. Stainken, E O Assanah, P D Khare, Robin Davies, N J Espat, Richard P. Junghan...> ;Cancer Gene Therapy. 2014 Oct 3
20 citations
T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay, Hans-Peter Kiem, David Baltimore, Marina O'Reilly, Renier J Brentjens, Laurence Cooper, Stephen Forman, Stephen Gottschalk, Philip Greenberg...> ;Molecular Therapy. 2014 Sep 1
19 citations
A novel real‐time CTL assay to measure designer T‐cell function against HIV Env+ cells
Andrew G. MacLean, Edith M. Walker, Gautam K. Sahu, Gail Skowron, Preston A. Marx, Dorothee von Laer, Richard P. Junghans, Stephen E. Braun> ;Journal of Medical Primatology. 2014 Oct 1
8 citations
Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.
Ahmad Samer Al-Homsi, Zhongbin Lai, Tara S. Roy, M. Monzr Al-Malki, Nicholas Kouttab, Richard P. Junghans> ;Transplant Immunology. 2014 Jan 1
Recombination-deletion between homologous cassettes in retrovirus is suppressed via a strategy of degenerate codon substitution.
Eung Jun Im, Anthony Bais, Wen Yang, Qiangzhong Ma, Xiuyang Guo, Steven M Sepe, Richard P. Junghans> ;Molecular Therapy. Methods & Clinical Development. 2014 Jan 1
38 citations
Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy
Qiangzhong Ma, Erica M. Gomes, Agnes Lo, Richard P. Junghans> ;The Prostate. 2014 Feb 1
Join now to see all

Hospital Affiliations

Morton Hospital and Medical CenterTaunton, Massachusetts